GlassScriptPhysician profile
Lenard L Malmin
NPI 1255908489
$991.24
in general payments reported to CMS, 2019-2025
25 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $192 · 2024: $471 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $109.53 | 2024 | |
| Corium, LLC | $109.04 | 2024-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.48 | 2023-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $79.39 | 2024-2025 | Fanapt |
| Tris Pharma INC | $60.49 | 2024-2025 | Dyanavel Xr |
| Abbvie INC. | $58.67 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $47.57 | 2025 | Austedo Xr |
| Alkermes, INC. | $41.49 | 2024-2025 | Lybalvi, Aristada |
| Halozyme INC | $39.79 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $36.19 | 2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $33.73 | 2024-2025 | Xyosted, Qelbree |
| Amgen INC. | $30.38 | 2023 | Prolia, Evenity |
| E.R. Squibb & Sons, L.L.C. | $27.97 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $27.74 | 2024 | Ingrezza |
| Exeltis, USA INC. | $23.39 | 2023 | Slynd |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.92 | 2025 | Invega Sustenna |
| Braeburn INC. | $20.98 | 2023 | Brixadi |
| Idorsia Pharmaceuticals US INC | $20.88 | 2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $18.18 | 2025 | Jornay Pm |
| Indivior INC. | $17.72 | 2024 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.85 | 2025 | Rejoyn |
| Novo Nordisk INC | $16.04 | 2023 | Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $14.35 | 2025 | Auvelity |
| Lundbeck LLC | $13.88 | 2025 | Rexulti |
| Lilly USA, LLC | $13.59 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenard Malmin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.